Zeus Sleep Completes Fundraise to Facilitate Sales of Breakthrough Anti-Snoring Device

The team at Zeus Sleep are on a mission to give the world a better, healthier night’s sleep with their revolutionary devices which tackle the common problem of snoring and the medical problem of obstructive sleep apnoea (OSA).

Zeus, a consumer product, has been beta tested and has received very positive reviews and independent endorsements. Commercial sales are due to begin in May 2025 and the price point will provide access to millions of potential customers whilst generating a strong profit margin.

ZeusOSA, a medical device for treating OSA, has successfully completed another clinical trial, the latest being a collaboration with Dorset Hospital in 2024. The results of this trial, along with data from previous studies, provide strong evidence to seek approval from regulatory authorities for market release as a medical device, with the process expected to conclude early next year.

The company’s technology, which is protected by 13 patents, has been developed in collaboration with the UK’s two leading respiratory institutions – King's College London and Guy's and St Thomas' NHS Foundation Trust – and double-Queen’s-Award-winning B Corp Morgan Innovation & Technology.

It stems from 13 years of medical research by world-renowned sleep expert Professor Joerg Steier, who also sits on the company’s board.

Joerg is a professor of respiratory and sleep medicine at King’s College London, and a consultant at the Lane Fox Respiratory Unit at Guy’s and St Thomas’ Hospital. He is also a committee member of the British Thoracic Society, a European Respiratory Society task force member, and Honorary Secretary of the British Sleep Society.

The Zeus team also includes:

• Nigel Clarke (CEO and Co-founder), who is the CEO of manufacturing firm Morgan Innovation & Technology, where he has over 20 years’ experience in medical device development and commercialisation. During Covid-19, Nigel created the capability to manufacture 6,000 patient tracking devices per week to enable the Pfizer vaccine rollout.
• James Quest (CTO and Co-founder), who has spent ten years heading up Morgan Innovation & Technology’s R&D, Quality and regulatory department. He is a specialist in bringing devices to market, with two products which have been FDA approved in the past 18 months.
• Steve Waring (CFO), who specialises in supporting entrepreneur-led organisations across all growth stages, with two successful start-up to sale journeys (Fallon London sold to Publicis SA and 101 London sold to IPG). Broad experience across businesses with revenue from £0-£140 million, including Saatchi and Saatchi UK and Fallon globally.
• Jane Gray (Sales & Marketing Director), who led brand strategy for nationwide early years provider Storal, spearheading campaigns for new acquisitions and enabling substantial multi-site growth. She directed go-to-market strategies for AQA's product portfolio, achieving significant market share, and has led global campaigns for major brands at agencies including McCann Erickson.

Paul Boon, Head of Financial Analysis at Growthdeck, says:

“Chronic snoring affects up to a quarter of the global adult population and harms sufferers' health, quality of life and their relationships.”

“Due to the substantial market size and strong customer desire to solve this debilitating daily problem, many companies have tried to prevent or reduce its adverse effects. Until now, only expensive and/or intrusive medical technologies and surgeries have worked.”

“This breakthrough offers a non-invasive, effective, affordable and portable solution, making it accessible to millions.”

“We are excited to be backing the team at Zeus Sleep, who have proven sales interest, an existing waitlist and distributors ready to sell.”

“The outstanding success of the fundraise highlights Growthdeck and our network’s strong commitment to backing ambitious, high-growth UK businesses.”